Skip to main
ZVRA
ZVRA logo

ZVRA Stock Forecast & Price Target

ZVRA Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zevra Therapeutics Inc. is demonstrating strong momentum in its sales trajectory, particularly with the launch of its drug MIPLYFFA for Niemann-Pick type C, which reported $10.1 million in sales during the first quarter—significantly surpassing initial estimates. The company has seen a substantial increase in patient enrollment, with 109 treatment enrollment forms as of December 31, 2024, indicating robust demand for its therapies. With ongoing awareness campaigns and a targeted expansion strategy, Zevra is positioned for continued sales growth into 2025, bolstered by a strong early pipeline of patients transitioning to paid drug coverage.

Bears say

Zevra Therapeutics Inc. is currently grappling with substantial financial challenges, including a significant GAAP net loss of $20.4 million and a larger net loss of $35.7 million in the fourth quarter, which raises concerns about the company's financial sustainability. Additionally, the company faces risks from emerging competitor approvals, slow drug launch trajectories, and poor payer coverage, all of which could hinder sales growth and overall market penetration. With a history of losses and an ongoing struggle to achieve profitability, the prospect for Zevra's financial recovery appears bleak, especially if pipeline setbacks occur or if partnerships cannot be secured on favorable terms.

ZVRA has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zevra Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zevra Therapeutics Inc (ZVRA) Forecast

Analysts have given ZVRA a Strong Buy based on their latest research and market trends.

According to 8 analysts, ZVRA has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zevra Therapeutics Inc (ZVRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.